-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 12, Chengdu Bite Pharmaceutical was the first to submit a 4-type generic application for dacomitinib tablets
.
Pfizer's dacomitinib tablets were officially approved for marketing in China in 2019, and successfully entered the National Medical Insurance List by the end of 2021.
This product is the only lung cancer targeted drug that has proven overall survival benefit in Asian populations
.
Figure 1: The latest product status of Bite Pharmaceuticals Source: Pfizer’s dacomitinib tablets were officially approved for marketing in China in May 2019, and can be used as a single drug for epidermal growth factor receptor (EGFR) No.
19 First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with exon deletion mutation or exon 21 L858R substitution mutation
.
This product is the only targeted therapy that has demonstrated an overall survival (OS) benefit at the 21L858R locus and in Asian populations in clinical trials
.
Figure 2: Sales of Pfizer’s dacomitinib tablets in the retail market (unit: 100 million yuan) Source: Minet.
com China’s urban physical pharmacy terminal layout Physical pharmacy terminals are rapidly increasing the volume.
In 2020, sales have exceeded 110 million yuan, with a growth rate of 240%.
In 2021, it is expected to achieve a new achievement of 190 million yuan
.
Earlier, the product has not been included in medical insurance.
In 2020, the sales of dacomitinib tablets in urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as the terminals of Chinese public medical institutions) will be around 50 million yuan.
, With the successful entry of the product into the 2021 edition of the National Medical Insurance Negotiation Catalogue, 2022 will be the beginning of the hospital's heavy volume
.
Figure 3: 2021E retail market protein kinase inhibitor TOP20 varieties Source: Minet.
com China's urban entity pharmacy terminal layout The production approval for lenvatinib capsules, the dacomitinib tablets reported this time will become the company's second tinib product
.
According to the data from Minet.
com, in 2021, lenvatinib and dacomitinib will be included in the TOP20 varieties of protein kinase inhibitors in Chinese urban physical pharmacy terminals, and the market potential can be expected
.
.
Pfizer's dacomitinib tablets were officially approved for marketing in China in 2019, and successfully entered the National Medical Insurance List by the end of 2021.
This product is the only lung cancer targeted drug that has proven overall survival benefit in Asian populations
.
Figure 1: The latest product status of Bite Pharmaceuticals Source: Pfizer’s dacomitinib tablets were officially approved for marketing in China in May 2019, and can be used as a single drug for epidermal growth factor receptor (EGFR) No.
19 First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with exon deletion mutation or exon 21 L858R substitution mutation
.
This product is the only targeted therapy that has demonstrated an overall survival (OS) benefit at the 21L858R locus and in Asian populations in clinical trials
.
Figure 2: Sales of Pfizer’s dacomitinib tablets in the retail market (unit: 100 million yuan) Source: Minet.
com China’s urban physical pharmacy terminal layout Physical pharmacy terminals are rapidly increasing the volume.
In 2020, sales have exceeded 110 million yuan, with a growth rate of 240%.
In 2021, it is expected to achieve a new achievement of 190 million yuan
.
Earlier, the product has not been included in medical insurance.
In 2020, the sales of dacomitinib tablets in urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as the terminals of Chinese public medical institutions) will be around 50 million yuan.
, With the successful entry of the product into the 2021 edition of the National Medical Insurance Negotiation Catalogue, 2022 will be the beginning of the hospital's heavy volume
.
Figure 3: 2021E retail market protein kinase inhibitor TOP20 varieties Source: Minet.
com China's urban entity pharmacy terminal layout The production approval for lenvatinib capsules, the dacomitinib tablets reported this time will become the company's second tinib product
.
According to the data from Minet.
com, in 2021, lenvatinib and dacomitinib will be included in the TOP20 varieties of protein kinase inhibitors in Chinese urban physical pharmacy terminals, and the market potential can be expected
.
